PERFORMANCE AND IMAGE ENHANCING DRUGS

Similar documents
Background: Kirketon Road Centre

Needle and Syringe Programs - 17 October 2013

Rachel Rowe, Israel Berger Drug & Alcohol Multicultural Education Centre. Jan Copeland. National Cannabis Prevention and Information Centre

New South Wales Needle and Syringe Program Enhanced Data Collection

PH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes

Harm Reduction in Nigeria

Blood-borne viruses in marginalised populations

QuADS Organisational Standards and Professional Competencies in needle exchange

Poland nationalupdate

Tajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Promoting hepatitis B vaccination

AUSTRALIAN NSP SURVEY NATIONAL DATA REPORT

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study

Guidelines For Services Providing Injecting Equipment

Government of Canada Federal AIDS Initiative Milestones

Update on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018

Dr Vivian Hope. Health Protection Agency, London. 19 th Annual Conference of the British HIV Association (BHIVA)

AUSTRALIAN NSP SURVEY

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Feedback from joint country mission on HIV and hepatitis B and C of ECDC and EMCDDA experts to Latvia, September 2014

Technical Guidance Note for Global Fund HIV Proposals

HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report

Methods: respondent driven sampling (RDS) was used to recruit PWID

Prevention of and Immunisation against Hepatitis B and C

Notes Detection of Hepatitis B and C in Primary Care

COUNTRY TABLE. MONTENEGRO.

Signs of success latest national NESI data?

>Hepatitis NSW will continue to

Detection of Hepatitis B and C in Primary Care

Welcome to Your Reading Assignment

Strategies of drug users to avoid infection with hepatitis C

As a result of this training, participants will be able to:

Models of good practice in drug treatment in Europe. Project group

Sydney Medically Supervised Injecting Centre Evaluation Report No. 4: Evaluation of service operation and overdose-related events

Victorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017

Needle Exchange Programs

Targeted Outreach & Other Strategies for Increasing HCV Testing

Crack Pipe FAQs: What service providers need to know. Presenter: Andrew Ivsins

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

Harm Reduction Database Wales: Needle and Syringe provision

COLLABORATIVE RESEARCH ON HIV AMONG PERSONS WHO INJECT DRUGS IN TALLINN, ESTONIA, PRESENT

PREVENTION STRATEGIES RELATED TO HIV/AIDS Narra Smith Cox, Ph.D., CHES

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

As a result of this training, participants will be able to:

Hepatitis C Strategy. About us. What is hepatitis C?

UNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,

New trends in harm reduction in Europe: progress made challenges ahead

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

Question 1. Blood Borne Viruses: Some important basic facts 6. What does BBV stand for? A. Blood Based Virus. B. Blood Borne Viruses

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

Prevention of and Immunisation against Hepatitis B and C

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Recent trends in drug problems and service provision in Greece

Greater Manchester Commissioning Guidelines for Blood Borne Virus Prevention

Substance use and misuse

That s SIC: Mobilising peer networks for hepatitis C

Improving NSP and Harm Reduction Services. Jason Farrell, European HCV and Drug Use Initiative

Transmission/Prevention

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

Integrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson

Training Objectives. By the end of this session you will be able to: 2. Recognize key principles of harm reduction.

Key findings from the 2014 Illicit Drug Reporting System

Drug Consumption Rooms Worldwide

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

Overview. HIV and the First Peoples of Australia Our Story, Our Time, Our Journey. Social Determinants of Health. Our Story Education.

Mr James McVeigh Liverpool John Moores University

Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

National HIV Behavioral Surveillance Portland, Oregon

Substance Misuse Treatment Framework (SMTF) Service Framework for Needle and Syringe Programmes in Wales

Presenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin

What is Drug Trends? funded by the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Advancing the National HIV/AIDS Strategy: Housing and the HCCI. Housing Summit Los Angeles, CA

San Francisco Suicide Prevention (SFSP) Client Satisfaction Report July 1, 2011 to June 30, 2012 Key Findings and Implementation of Feedback

IMPORTANCE OF PEER-BASED SERVICES & NEEDLE & SYRINGE PROGRAMS (NSP)

NEEDLE AND SYRINGE PROGRAMMES MONITORING IN LITHUANIA

Syringe Exchange Research Update Harm Reduction Coalition August 2008

Substance use and misuse

Informal Outreach. Objectives. module. module

Re: Revisions to the Communicable Disease Control Manual, Chapter 3- Infection Control

Drug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD

Part of the Continuum of Care. Harm Reduction. Gino Vumbaca President Harm Reduction Australia

HIV Risk Behaviour in Irish Intravenous Drug Users

Understanding HIV/AIDS: The current state of the HIV epidemic in British Columbia Mark Gilbert, MD, MHSc, FRCPC

HIV/AIDS INDICATORS. AIDS Indicator Survey 8 Basic Documentation Introduction to the AIS

Becoming a harm reduction distribution agency in Toronto - information session

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Hepatitis prevention in the context of HIV prevention point work in Latvia

Challenges and solutions for. life span. June 2011

Annual Surveillance Report HIV, viral hepatitis and sexually transmissible infections in Australia

Hepatitis B Virus and the Opioid Crisis

DEPARTMENT OF HEALTH RESPONSE TO KEY POPULATIONS

The National Hepatitis C Plan - Scotland

Medical Director. and in prison settings in Romania. Ministry of Justice National Administration of Penitentiaries L IŢ

2010 HIV Prevention Plan and HIV Prevention Section Update

Blood Borne Viral Hepatitis Action for Wales Research Programme Developing the evidence base Findings, Implications and Recommendations

Prevention of and Immunisation against Hepatitis B and C

Transcription:

PERFORMANCE AND IMAGE ENHANCING DRUGS Injectors access to needle syringe programs Presented at the 2014 National Drug Trends Conference Sydney 20 October 2014 Dr Karen J Chronister

Overview Background Survey results Discussion and next steps

Kirketon Road Centre (KRC) Service aim: to prevent, treat, and care for HIV/AIDS and other transmissible infections among the following target populations People who inject drugs (PWID) Sex workers At risk young people (less than 25 years) Needle and Syringe, outreach, and Methadone Access Programs integrated into a targeted primary health care model

Needle & Syringe Program (NSP) An evidence based public health program that aims to protect the community from the spread of infections such as HIV and hepatitis C among people who inject drugs Effects sustainable behaviour change among some of the most marginalised groups in society Specifically designed to maximise access by people otherwise least likely to attend health services

Background Increasing use of performance and image enhancing drugs (PIEDs) in recent years Unknown size and nature of a largely hidden population PIED injectors increasingly accessing NSP to obtain free injecting equipment Significant cost and capacity implications Presents a significant public policy dilemma for the NSP, particularly in the context of removal of limits to increase coverage among PWID

The Survey Aim: to assess blood-borne infection (BBI) risk among PIEDs injectors who access NSP services to inform appropriate service delivery Participants: clients attending KRC s NSP services who reported injection of PIEDs Time period: November 2013 January 2014 Location: KRC and Clinic 180, both in Kings Cross

KRC or Clinic 180 Service Access First attendance Referral sources % Less than 3 months ago 28 3 6 months ago 0 6 12 months ago 16 1 5 years ago 42 More than 5 years ago 14 KRC, Outreach Bus 5% External agency 6% Internet 14% Word of mouth - friends, partner, gym 64% Other 11%

Sources of Injecting Equipment 44% obtain injecting equipment for others 55% obtain injecting equipment elsewhere Pharmacy/chemist = 21 participants Friends = 15 participants Internet = 8 participants Other NSPs = 7 participants Doctor = 6 participants Gym = 3 participants

Survey Participants 103 participants All but one participant was male Mean age = 32.6 (± 8.5) years 42% identified as gay or bisexual

Injecting History 101 reported never re-using injecting equipment after someone else 40 35 Age at first PIEDs injection 6 participants ever injected intravenously Mean age = 27.6 years None re-used or shared equipment 1 HIV positive 30 25 20 15 10 5 0 Less than 25 years 25-34 years 35-44 years 45 years and older

Blood-borne Infections 35 30 25 20 15 10 5 0 BBI Testing HIV HCV HIV prevalence 4 positive participants 52 never tested or did not answer Hepatitis C prevalence 0 positive participants 63 never tested or did not answer

Comparing heterosexual and gay/bisexual participants Heterosexual Gay or bisexual N % N % P-value Age group 0.002 Less than 25 years 15 25.4 1 2.3 25 34 years 28 47.5 18 41.9 35 44 years 10 16.9 18 41.9 45 years and older 6 10.2 6 13.9 Age at first PIED injection 0.001 Less than 25 years 29 52.7 7 17.5 25 34 years 17 30.9 14 35.0 35 44 years 7 12.7 17 42.5 45 years and older 2 3.6 2 5.0 Ever injected intravenously 3 5.2 3 7.0 0.704 Ever tested for HIV 26 47.3 35 92.1 < 0.001 Ever tested for HCV 22 57.9 24 82.8 0.030

Other Factors HIV positive (n=4) All gay or bisexual and previously tested for HCV 1 injected intravenously None re-used equipment after someone else or been in prison Prison history (n=1) Did not inject in prison, re-use equipment after someone else, or inject intravenously

Health Service Needs Almost all said no, none, or no thanks You guys are doing a great job! Animal services

Conclusions PIEDs injectors attending KRC have low BBI risk Findings specific to KRC only May be different in other NSP services Continue to focus public health effort on those people who inject drugs who are at continuing high risk of BBI

Implications Commenced provision of stop-gap packs Limited quantity of needles and syringes, information re health risks specific to PIEDs use, injecting risk behaviour, BBIs, IRID, safer sex, and alternative sources of equipment Promote BBI testing and other relevant services Provide referrals as needed Promote alternative sources of affordable equipment Facilitate capacity of local pharmacies to meet needs

Acknowledgements Co-authors A/Prof Ingrid van Beek and Mr Phil Tayler KRC Frontline Services Unit KRC clients For further information, please contact: Kirketon Road Centre PO Box 22 Kings Cross NSW 1340 + 61 2 9360 2766